Bristol-Myers Squibb Co. (BMYMP)
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
📉 **NEGATIVE** • Low confidence analysis (52%) • Mild negative clinical indicator • Limited downside risk **Sentiment:** Negative (45%) **Content type:** Clinical